Clinical Trial Update: Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating microdosed atropine eye drops (0.1% and 0.01%) for slowing pediatric myopia progression has been terminated. Sponsor: Eyenovia Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• Atropine 0.01% ophthalmic solution (atropine)
• Atropine 0.1% ophthalmic solution (atropine)

Snippet

Sponsor: Eyenovia Inc. | Conditions: Myopia | Phase 3 | Status: TERMINATED